MedPacto's 'Bactosertib and Polfox Combination Therapy for Pancreatic Cancer' Accepted as Poster at US AACR Pancreatic Cancer Conference
[Asia Economy Reporter Lee Gwan-joo] MedPacto announced on the 1st that the interim clinical data of the combination therapy of Bektosertib for pancreatic cancer has been selected as a poster at the AACR Special Conference on Pancreatic Cancer.
The AACR Special Conference on Pancreatic Cancer, held from September 13 to 16 in Boston, USA, will reveal various clinical data related to pancreatic cancer treatment.
At this conference, MedPacto plans to present interim clinical 1b (investigator-initiated) data on the combination therapy of Bektosertib and FOLFOX for pancreatic cancer as a poster. The data to be disclosed this time includes overall survival (OS) data in addition to the interim clinical 1b data on the FOLFOX combination therapy that was revealed at the American Society of Clinical Oncology (ASCO) in June.
In the interim clinical 1b data disclosed at ASCO, among 13 patients who received 200 mg of Bektosertib twice daily, the objective response rate (ORR) was 23.1%, and 38.5% were confirmed as stable disease (SD) where the tumor did not grow further. The resulting clinical benefit was 61.5%. The median progression-free survival (mPFS) was 4.2 months. In contrast, the mPFS for FOLFOX as a second-line therapy in gemcitabine-failed patients was 1.7 months, with an ORR of 0%. For reference, the mPFS for first-line therapy in pancreatic cancer patients was 4 months.
A MedPacto official explained, "The clinical data disclosed this time confirmed that the combination therapy of Bektosertib and FOLFOX in pancreatic cancer patients shows significantly superior therapeutic effects compared to existing treatment regimens."
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051914165468840_1779167814.png)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- "I'll Stop by Starbucks Tomorrow": People Power Chungbuk Committee and Geoje Mayoral Candidate Face Criticism for Alleged 5·18 Demeaning Remarks
- [New York Stock Exchange] All Major Indices Close Lower as U.S. Treasury Yields Surge
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
Meanwhile, in addition to the clinical trials on the combination therapy of Bektosertib and FOLFOX, MedPacto is also conducting investigator-initiated clinical trials on the combination therapy of Bektosertib with 5FU/LV/Onivyde for pancreatic cancer. MedPacto plans to apply to the U.S. Food and Drug Administration (FDA) this year for a phase 2 clinical trial for approval purposes on the combination therapy of Bektosertib with 5FU/LV/Onivyde.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
